Microgynon 30 Ed

Ethinylestradiol, the active ingredient in Microgynon 30 Ed, is a synthetic estrogen presented as a combined tablet for oral use. It prevents pregnancy in women of reproductive age when taken as directed. GNH USA supplies Microgynon 30 Ed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon 30 Ed is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle.

Contraception: provides reliable prevention of pregnancy when taken correctly. Menstrual cycle regulation: helps to regularise bleeding patterns and reduce dysmenorrhoea. Acne management: may improve acne associated with androgen excess.

Microgynon 30 Ed may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea or gastrointestinal discomfort. - Breast tenderness or enlargement. - Headache or migraine. - Breakthrough or spotting bleeding. - Weight fluctuation or fluid retention. - Mood changes or irritability.

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism). - Arterial thrombosis (stroke, myocardial infarction). - Severe hypertension or hypertensive crisis. - Hepatic adenoma or benign liver tumours. - Allergic reactions (rash, angio‑edema, anaphylaxis). - Visual disturbances or sudden loss of vision.

Before prescribing Microgynon 30 Ed, clinicians should assess individual risk factors and counsel patients on safe use.

Assess thrombotic risk: evaluate personal and family history of clotting disorders. Screen for cardiovascular disease: avoid in uncontrolled hypertension or recent myocardial infarction. Consider smoking status: contraindicated in women over 35 who smoke. Review liver function: contraindicated in active liver disease or tumours. Pregnancy and lactation: discontinue if pregnancy is confirmed; advise on breastfeeding considerations. Store at room temperature below 25°C: keep in the original packaging, protect from moisture and heat.

Microgynon 30 Ed can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) may reduce contraceptive efficacy. - Rifampicin or other potent inducers can lower hormone levels. - St. John’s wort herbal supplement may compromise protection. - Certain protease inhibitors (e.g., ritonavir) can affect hormone metabolism. - Antimicrobial agents such as griseofulvin may diminish effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole) may increase hormone concentrations. - SSRIs or SNRIs can heighten bleeding risk. - Antihypertensive drugs (e.g., ACE inhibitors) may require dose adjustment. - Ginseng or other herbal stimulants may affect hormone balance. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase cardiovascular risk when combined.